Platinum and Other Heavy Metal Compounds in Cancer Chemotherapy: Molecular Mechanisms and Clinical Applications

Front Matter....Pages i-xxvi
Platinum Compounds: The Culmination of the Era of Cancer Chemotherapy....Pages 1-7
Studies on New Platinum Compounds....Pages 11-17
Assessment of the In Vivo Antiproliferative Activity of a Novel Platinum Particulate Pharmacophore....Pages 19-25
Nanocapsules of Platinum-Based Anticancer Drugs....Pages 27-32
The Design and Development of the Tumor-Targeting Nanopolymer Dach Platinum Conjugate AP5346 (Prolindac ™ )....Pages 33-39
In vitro Anti-proliferative Effects of ProLindac™, a Novel Dach-Platinum-Linked Polymer Compound, as a Single Agent and in Combination with Other Anti-cancer Drugs....Pages 41-47
Synthesis of Cisplatin Analogues: Cytotoxic Efficacy and Anti-tumour Activity of Bis-Amidine and Bis-Iminoether Pt(II) Complexes....Pages 49-56
Ruthenium Drugs for Cancer Chemotherapy: An Ongoing Challenge to Treat Solid Tumours....Pages 57-66
X-ray Crystal Structure of a Monofunctional Platinum–DNA Adduct, cis -{Pt(NH 3 ) 2 -(Pyridine)} 2+ Bound to Deoxyguanosine in a Dodecamer Duplex....Pages 67-72
Osmium Arenes: A New Class of Potential Anti-cancer Agents....Pages 73-79
Resistance to Cisplatin Results from Multiple Mechanisms in Cancer Cells....Pages 83-88
CTR1 as a Determinant of Platinum Drug Transport....Pages 89-94
Regulation of the Export of Platinum-Containing Drugs by the Copper Efflux Transporters ATP7A and ATP7B....Pages 95-99
Altered Localization of Transport Proteins Associated with Cisplatin Resistance....Pages 101-107
How to Overcome Cisplatin Resistance Through Proton Pump Inhibitors....Pages 109-114
Cellular Resistance to Oxaliplatin and Drug Accumulation Defects....Pages 115-124
Possible Incorporation of Free N7 -Platinated Guanines in DNA by DNA Polymerases, Relevance for the Cisplatin Mechanism of Action....Pages 125-132
Structural and Mechanistic Studies of Anticancer Platinum Drugs: Uptake, Activation, and the Cellular Response to DNA Binding....Pages 135-147
Platinum Drugs and DNA Repair: Lessons from the NCI Panel and Clinical Correlates....Pages 149-155
Differences in Conformation and Conformational Dynamics Between Cisplatin and Oxaliplatin DNA Adducts....Pages 157-169
Regrowth Resistance: Low-Level Platinum Resistance Mediated by Rapid Recovery from Platinum-Induced Cell-Cycle Arrest....Pages 171-176
Targeting Nucleotide Excision Repair as a Mechanism to Increase Cisplatin Efficacy....Pages 177-187
CHK2 and ERCC1 in the DNA Adduct Repair Pathway that Mediates Acquired Cisplatin Resistance....Pages 189-194
Modulation of Survival Pathways in Ovarian Carcinoma Cells Resistant to Platinum Compounds....Pages 195-200
Paraptotic Cell Death Induced by the Thioxotriazole Copper Complex A0: A New Tool to Kill Apoptosis-Resistant Cancer Cells....Pages 201-207
Platinum Compounds and Radiation....Pages 211-223
Treating Cisplatin-Resistant Cancer: A Systematic Analysis of Oxaliplatin or Paclitaxel Salvage Chemotherapy....Pages 225-230
Platinum Compounds in Lung Cancer: Current Status....Pages 231-242
Is Lipoplatinum Monotherapy an Active Alternative in Second Line Treatment of Metastatic Non–Small Cell Lung Cancer? A Phase II Trial....Pages 243-249
Combining Platinums in Gastric Cancer....Pages 251-270
Oxaliplatin-Based Chemotherapy for Colon Cancer....Pages 271-284
First-Line Systemic Chemotherapy with Folfoxiri Followed by Radical Surgical Resection of Metastases for the Treatment of Unresectable Metastatic Colorectal Cancer Patients....Pages 285-293
Pre-operative Radio-Chemotherapy of Rectal Cancer: Toxicity and Preliminary Results with the Addition of Weekly Oxaliplatin....Pages 295-306
The Role of Platins in Newly Diagnosed Endometrial Cancer....Pages 307-315
Platinum Compounds: Key Ingredients in Ovarian Cancer Treatment and Strategies....Pages 317-328
Intraperitoneal Chemotherapy: An Important Strategy in Ovarian Cancer Treatment....Pages 329-333
Novel Strategies for Enhancing the Efficacy of Intraperitoneal Chemotherapy for Patients with Ovarian Cancer....Pages 335-341
Laparoscopically Assisted Heated Intra-Operative Intraperitoneal Chemotherapy (HIPEC): Technical Aspect and Pharmacokinetics Data....Pages 343-351
Organic Cation Transporters 2 as Mediators of Cisplatin Nephrotoxicity....Pages 353-358
Peripheral Neurotoxicity of Platinum Compounds....Pages 359-364
Platinum Drugs in Children with Cancer....Pages 365-371
Optimising Carboplatin Dose using Patient Characteristics and Therapeutic Drug Monitoring....Pages 373-380
Back Matter....Pages 379-383